Cite
HARVARD Citation
Mulleners, W. et al. (2022). 200 A randomized, placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: double-blind results from CONQUER. Journal of neurology, neurosurgery and psychiatry. 93 (6), p. A70. [Online].